Skip to main content
SpringerLink
Log in

β3-Agonists for Overactive Bladder

  • Chapter
  • First Online:
Contemporary Pharmacotherapy of Overactive Bladder

Abstract

Medical management of overactive bladder (OAB) has traditionally been with anticholinergic medications. While this drug class is effective for some patients, efficacy is not seen in all, and the side effect profile may result in decreased use. Mirabegron, a β3-adrenoceptor agonist, has been established as an alternative therapy. This chapter aims to review the history of mirabegron in addition to drug safety, efficacy, and reliability in a diverse group of patients including the elderly, those with cardiac comorbidities, and those with bladder outlet obstruction. Drug cost and comparison to anticholinergics and placebo is also addressed in this review. A growing body of evidence suggests that mirabegron is a safe and efficacious drug with a limited side effect profile rendering it as a potential first-line pharmacological option for the management of OAB.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AE:

Adverse effects

BID:

Twice daily

BIM:

Budget income model

BMI:

Body mass index

BOO:

Bladder outlet obstruction

BPM:

Beats per minute

DBP:

Diastolic blood pressure

HR:

Heart rate

HRQOL:

Health-related quality of life

HTN:

Hypertension

LUTS:

Lower urinary tract symptoms

NDO:

Neurogenic detrusor overactivity

OAB:

Overactive bladder

OAB-qSS:

Overactive bladder questionnaire symptom score

PPBC:

Patient perception of bladder control

PVR:

Post-void residual

Qmax:

Maximum flow

Qmaxpdet:

Detrusor pressure at maximum flow

SBP:

Systemic blood pressure

TEAE:

Treatment emergent adverse effect

TS-VAS:

Treatment satisfaction-visual analog scale

UDS:

Urodynamics

UI:

Urinary incontinence

UTI:

Urinary tract infection

References

  1. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132–8.

    Article  Google Scholar 

  2. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ; American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. 2012; amended 2014. http://www.auanet.org/guidelines/overactive-bladder-(oab)-(aua/sufu-guideline-2012-amended-2014). Accessed 27 Apr 2018.

  3. D’Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence and switch rates among extended release and immediate release overactive medications in a regional managed care plan. J Manag Care Pharm. 2008;14(3):291–301.

    PubMed  Google Scholar 

  4. Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder. Neurourok Urodyn. 2007;26(6):752–6.

    Article  CAS  Google Scholar 

  5. Yamaguchi O. Beta3-adrenoceptors in human detrusor muscle. Urology. 2002;59(5 Suppl 1):25–9.

    Article  Google Scholar 

  6. Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321(2):642–7.

    Article  CAS  Google Scholar 

  7. Sacco E, Bienstinesi R, Tienforti D, Racioppi M, Gulino G, D’Agostino D. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discovery. 2014;9(4):433–48.

    Article  CAS  Google Scholar 

  8. Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, et al. Absorption, metabolism and excretion of mirabegron (YM178), a potent and selective β3-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012;40(4):815–24.

    Article  CAS  Google Scholar 

  9. Takusagawa S, Miyashita A, Iwatsubu T, Usui T. In vitro inhibition and induction of human cytrochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist. Xenobiotica. 2012;42(12):1187–96.

    Article  CAS  Google Scholar 

  10. Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist. Xenobiotica. 2012;42(10):957–67.

    Article  CAS  Google Scholar 

  11. Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, et al. Role of cytochrome P450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3 adrenoceptor agonist. Clin Drug Investig. 2013;33(6):429–40.

    Article  CAS  Google Scholar 

  12. Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, et al. The effect of mirabegron a potent and selective β3 adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet. 2014;39(1):43–52.

    Article  CAS  Google Scholar 

  13. Iitauska H, van Gelderen M, Katashima M, Takusagawa S, Sawamoto T. Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder in healthy East Asian subjects. Clin Ther. 2015;37(5):1031–44.

    Article  Google Scholar 

  14. Lee J, Zhang W, Moy S, Kowalski D, Kerbusch V, van Gelderen M, et al. Effects of food intake on pharmacokinetic properties of mirabegron oral controlled-absorption system: a single dose, randomized, crossover study in healthy adults. Clin Ther. 2013;35(3):333–41.

    Article  CAS  Google Scholar 

  15. Krhut J, Martan A, Zachoval R, Hanus T, Svabik K, Zvara P. Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females. Eur J Obstet Gynecol Reprod Biol. 2016;196:64–8.

    Article  CAS  Google Scholar 

  16. Chapple CR, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele JJ, Bosman B, et al. Dragon Investigator Group. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24(9):1447–58.

    Article  Google Scholar 

  17. Chapple CR, Amarenco G, López Aramburu MA, Everaert K, Liehne J, Lucas M, Vik V, et al. BLOSSOM Investigator Group. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013;32(8):1116–22.

    Article  CAS  Google Scholar 

  18. Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(1):17–30.

    Article  CAS  Google Scholar 

  19. Coyne KS, Martza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC). A single item global measure for patients with overactive bladder. Eur Urol. 2006;49(6):1079–86.

    Article  Google Scholar 

  20. Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–95.

    Article  CAS  Google Scholar 

  21. Myrbetriq™ (mirabegron) extended-release tablets, for oral use. Initial U.S. Approval: Revised June 2012. Northbrook: Astellas Pharma US, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202611s000lbl.pdf. Accessed 4 May 2018.

  22. Kosilov K, Loparev S, Ivanovskaya M, Kosilova L. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Arch Gerontol Geriatr. 2015;61(2):212–6.

    Article  CAS  Google Scholar 

  23. Sebastianelli A, Russo G, Kaplan SA, McVary KT, Moncada I, Graves S, et al. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: comparison with placebo and tolterodine. Int J Urol. 2018;25(3):196–205.

    Article  CAS  Google Scholar 

  24. Robinson D, Kelleher C, Staskin D, Mueller ER, Falconer C, Wang J, et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourol Urodyn. 2018;27(1):394–406.

    Article  Google Scholar 

  25. Zacche MM, Giarenis TG, Robinson D, Cardozo L. Is there an association between aspects of the metabolic syndrome and overactive bladder? A prospective cohort study in women with lower urinary tract symptoms. Eur J Obstet Gynecol Reprod Biol. 2017;217:1–5.

    Article  CAS  Google Scholar 

  26. Subak LL, Whitcomb E, Shen H, Saxton J, Vittinghoff E, Brown JS. Weight loss: a novel and effective treatment for urinary incontinence. J Urol. 2005;174(1):190–5.

    Article  Google Scholar 

  27. Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011;65(4):487–507.

    Article  CAS  Google Scholar 

  28. Martín-Merino E, García-Rodríguez LA, Massó-González EL, Roehrborn CG. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol. 2009;182(4):1442–8.

    Article  Google Scholar 

  29. Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE. Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4):1320–7.

    Article  CAS  Google Scholar 

  30. Wöllner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54(1):78–82.

    Article  Google Scholar 

  31. Saraf AA, Petersen AW, Simmons SF, Schnelle JF, Bell SP, Kripalani S, et al. Medications Associated with geriatric syndromes and their prevalence in older hospitalized adults discharged to skilled nursing facilities. J Hosp Med. 2016;11(10):694–700.

    Article  Google Scholar 

  32. Bunniran S, Davis C, Kristy R, Ng D, Schermer CR, Uribe C, Suehs BT. A prospective study of elderly initiating mirabegron versus antimuscarinics: patient reported outcomes from the overactive bladder satisfaction scales and other instruments. Neurourol Urodyn. 2018;37(1):177–85.

    Article  CAS  Google Scholar 

  33. Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M. Effects of renal or hepatic impairment on the pharmacokinetics of mirabegron. Clin Drug Investig. 2013;33(1):11–23.

    Article  CAS  Google Scholar 

  34. Vij M, Drake MJ. Clinical use of the β3 adrenoceptor agonist mirabegron in patients with overactive bladder syndrome. Ther Adv Urol. 2015;7(5):241–8.

    Article  CAS  Google Scholar 

  35. Skeberdis VA, Gendviliene V, Zablockaite D, Treinys R, Macianskiene R, Bogdelis A, et al. beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current. J Clin Invest. 2008;118(9):3219–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Rosa GM, Ferrero S, Nitti VW, Wagg A, Saleem T, Chapple CR. Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol. 2016;69(2):311–23.

    Article  CAS  Google Scholar 

  37. Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, Coyne KS. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65(5):567–85.

    Article  CAS  Google Scholar 

  38. Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin. 2007;23(1):65–76.

    Article  Google Scholar 

  39. Martan A, Masata J, Krhut J, Zachoval R, Hanus T, Svabik K. Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study. Eur J Obstet Gynecol Reprod Biol. 2017;210:247–50.

    Article  CAS  Google Scholar 

  40. Haab F, Castro-Diaz D. Persistence with antimuscarinic therapy in patiens with overactive bladder. Int J Clin Pract. 2005;59(8):931–7. Review

    Article  CAS  Google Scholar 

  41. Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–74.

    Article  CAS  Google Scholar 

  42. Staskin D, Herschorn S, Fialkov J, Tu LM, Walsh T, Schermer CR. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study). Int Urygonecol J. 2018;29(2):273–83.

    Article  Google Scholar 

  43. Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, Pashos CL. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526–32, 532.e1–e18.

    Google Scholar 

  44. Hu TW, Wagner TH. Health-related consequences of overactive bladder: an economic perspective. BJU Int. 2005;96(Suppl 1):43–5.

    Article  Google Scholar 

  45. Hu TW, Wagner TH, Bentkover JD, LeBlanc K, Piancentini A, Stewart WF, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003;61(6):1123–8.

    Article  Google Scholar 

  46. Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, et al. Estimated budget impact of increased use of mirabegron, a novel treatment for overactive bladder. J Manag Care Spec Pharm. 2016;22(9):1072–84.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vanderbilt University, Department of Urologic Surgery, Nashille, TN, USA

    Sophia Delpe Goodridge & Roger R. Dmochowski

Authors
  1. Sophia Delpe Goodridge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger R. Dmochowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger R. Dmochowski .

Editor information

Editors and Affiliations

  1. Department of Urology, Medical University of South Carolina, Charleston, SC, USA

    Lindsey Cox

  2. Department of Urology, Medical University of South Carolina, Charleston, SC, USA

    Eric S. Rovner

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Goodridge, S.D., Dmochowski, R.R. (2019). β3-Agonists for Overactive Bladder. In: Cox, L., Rovner, E. (eds) Contemporary Pharmacotherapy of Overactive Bladder. Springer, Cham. https://doi.org/10.1007/978-3-319-97265-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-97265-7_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-97264-0

  • Online ISBN: 978-3-319-97265-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation